The American Animal Hospital Association (AAHA) updated their diabetes mellitus guidelines in January this year. A small interesting section of note was their inclusion of incretins under ‘Non-Insulin Therapeutic Agents’.
An interesting set of three papers documenting the association between cognitive impairment and idiopathic epilepsy (IE) came out of the RVC this year. This is important as IE is the most common neurological condition in dogs with an onset of 6 months to 6 years.
There has been a lot of buzz online about a human diabetes paper suggesting diabetes may be more complex than historically thought. A paper in The Lancet: Diabetes and Endocrinology early this year suggests there may be as many as 5 types of diabetes in humans; instead of 2. This reminded me of a paper I had read in PLoS One regarding feline diabetes induced by hypersomatotropism.
A paper published earlier this year in Molecular Therapy detailed a successful dose dependent response of a usually fatal monogenic disorder of skeletal muscle in dogs to gene therapy. The disorder treated was X-Linked Myotubular Myopathy (XLMTM) which results from MTM1 gene mutations and deficiency in the protein that this gene encodes (myotubularin).
Mycoplasma, the smallest prokaryotic cell capable of cell replication, is a frequent annoyance to scientists and laboratory workers from contamination of painstakingly produced cell cultures. Present as natural flora on the mucosal surfaces of human and animals this organism is ubiquitous in nature.